Scientists have discovered an effective stem cell treatment to battle bone loss, that could help regenerate bones of osteoporosis patients and even astronauts. The novel therapy showed remarkable results in mice and is expected to enter human clinical trials in the next two years.
A clinical study conducted at Stanford School of Medicine demonstrated astounding recovery in chronic stroke patients after being treated with modified human stem cells. Several patients demonstrated seemingly miraculous regeneration in muscle movement and coordination literally overnight.
Scientists are making discoveries that change the way we live. Have you ever asked yourself about the revolutionary discoveries that have made a huge impact on our scientific way of thinking and our everyday life?
To many, it is coming off as a far-fetched dream, but aerial technology company EHang, and Lung Biotechnology, a subsidiary of pharmaceutical company United Therapeutics, have announced a new collaboration consisting of a 15-year plan to produce and utilize 1,000 unmanned drones for the transportation of manufactured transplant organs.
With all the talk about it in the scientific community, there is probably no surprise that this is yet another article discussing CRISPR. However, this may be one of the most profound discussions around the technology as it involves what could arguably be the potential flagship use of the gene editing tool – human therapy.
Advances in gene editing technology have spurred considerable progress towards a treatment for Duchenne muscular dystrophy (DMD). Although the disease is rare – affecting roughly 1 in 5,000 male births – its consequences are devastating: patients are confined to wheelchairs at an early age and often succumb to heart or respiratory failure in their twenties or thirties.
Meet Prof. Dr. Miomir Knežević, professor at the University of Ljubljana and a founder of several biotech companies.
INTERVIEW: “So Long, and Thanks For All the Stem Cells!” When It Comes to Stem Cell Treatment Animals Are Better Off
Meet Dr. Katerina Čeh, CEO of Animacel
Mesenchymal stromal cell use in treating severe graft-versus-host disease.